Long-term oral antiarrhythmic therapy with aprindine: Effects on cardiac function and adverse effects

H. Tsutsui, H. Araki, Y. Nagata, M. Nakamura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The effects of long-term aprindine administration on cardiac function were clinically investigated in seven patients with supraventricular or ventricular arrhythmias associated with organic heart disease. Three patients had normal cardiac function and four had various degrees of cardiac dysfunction before treatment with aprindine. The drug was administered orally in doses of 25 to 75 mg daily (mean ± SD, 54 ± 14 mg/day). The duration of follow-up ranged from six to 23 months (mean ± SD, 14 ± 6 months). An antiarrhythmic effect was achieved in five cases. No worsening or newly acquired symptoms or signs of cardiac dysfunction were recognized. No significant changes in end-diastolic dimension or ejection fraction were observed echocardiographically. Results of this study suggest that aprindine, which has been reported to have a negative inotropic action, does not cause significant deterioration of cardiac function even when given as long-term antiarrhythmic therapy to patients with cardiac dysfunction.

Original languageEnglish
Pages (from-to)770-777
Number of pages8
JournalClinical Therapeutics
Volume6
Issue number6
Publication statusPublished - Dec 1 1984

Fingerprint

Aprindine
Signs and Symptoms
Cardiac Arrhythmias
Heart Diseases
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Long-term oral antiarrhythmic therapy with aprindine : Effects on cardiac function and adverse effects. / Tsutsui, H.; Araki, H.; Nagata, Y.; Nakamura, M.

In: Clinical Therapeutics, Vol. 6, No. 6, 01.12.1984, p. 770-777.

Research output: Contribution to journalArticle

@article{a574fb0aac3e41aa804396879cd3d5a6,
title = "Long-term oral antiarrhythmic therapy with aprindine: Effects on cardiac function and adverse effects",
abstract = "The effects of long-term aprindine administration on cardiac function were clinically investigated in seven patients with supraventricular or ventricular arrhythmias associated with organic heart disease. Three patients had normal cardiac function and four had various degrees of cardiac dysfunction before treatment with aprindine. The drug was administered orally in doses of 25 to 75 mg daily (mean ± SD, 54 ± 14 mg/day). The duration of follow-up ranged from six to 23 months (mean ± SD, 14 ± 6 months). An antiarrhythmic effect was achieved in five cases. No worsening or newly acquired symptoms or signs of cardiac dysfunction were recognized. No significant changes in end-diastolic dimension or ejection fraction were observed echocardiographically. Results of this study suggest that aprindine, which has been reported to have a negative inotropic action, does not cause significant deterioration of cardiac function even when given as long-term antiarrhythmic therapy to patients with cardiac dysfunction.",
author = "H. Tsutsui and H. Araki and Y. Nagata and M. Nakamura",
year = "1984",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "770--777",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Long-term oral antiarrhythmic therapy with aprindine

T2 - Effects on cardiac function and adverse effects

AU - Tsutsui, H.

AU - Araki, H.

AU - Nagata, Y.

AU - Nakamura, M.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - The effects of long-term aprindine administration on cardiac function were clinically investigated in seven patients with supraventricular or ventricular arrhythmias associated with organic heart disease. Three patients had normal cardiac function and four had various degrees of cardiac dysfunction before treatment with aprindine. The drug was administered orally in doses of 25 to 75 mg daily (mean ± SD, 54 ± 14 mg/day). The duration of follow-up ranged from six to 23 months (mean ± SD, 14 ± 6 months). An antiarrhythmic effect was achieved in five cases. No worsening or newly acquired symptoms or signs of cardiac dysfunction were recognized. No significant changes in end-diastolic dimension or ejection fraction were observed echocardiographically. Results of this study suggest that aprindine, which has been reported to have a negative inotropic action, does not cause significant deterioration of cardiac function even when given as long-term antiarrhythmic therapy to patients with cardiac dysfunction.

AB - The effects of long-term aprindine administration on cardiac function were clinically investigated in seven patients with supraventricular or ventricular arrhythmias associated with organic heart disease. Three patients had normal cardiac function and four had various degrees of cardiac dysfunction before treatment with aprindine. The drug was administered orally in doses of 25 to 75 mg daily (mean ± SD, 54 ± 14 mg/day). The duration of follow-up ranged from six to 23 months (mean ± SD, 14 ± 6 months). An antiarrhythmic effect was achieved in five cases. No worsening or newly acquired symptoms or signs of cardiac dysfunction were recognized. No significant changes in end-diastolic dimension or ejection fraction were observed echocardiographically. Results of this study suggest that aprindine, which has been reported to have a negative inotropic action, does not cause significant deterioration of cardiac function even when given as long-term antiarrhythmic therapy to patients with cardiac dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0021705679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021705679&partnerID=8YFLogxK

M3 - Article

C2 - 6509460

AN - SCOPUS:0021705679

VL - 6

SP - 770

EP - 777

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -